Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes

Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes

(2013) D J Baker et al.   BRITISH JOURNAL OF PHARMACOLOGY

Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus

(2013) A. Kiyosue et al.   DIABETES OBESITY & METABOLISM

Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin

(2013) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Effects of a glucokinase activator on hepatic intermediary metabolism: study with13C-isotopomer-based metabolomics

(2012) Itzhak Nissim et al.   BIOCHEMICAL JOURNAL

Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour?

(2012) Matthew G Rees et al.   BRITISH JOURNAL OF PHARMACOLOGY

The use of animal models in diabetes research

(2012) Aileen JF King   BRITISH JOURNAL OF PHARMACOLOGY

Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans

(2012) Frédéric De Ceuninck et al.   BRITISH JOURNAL OF PHARMACOLOGY

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

(2012) L. A. Morrow et al.   DIABETES OBESITY & METABOLISM

Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp

(2012) M. Sjöstrand et al.   DIABETES OBESITY & METABOLISM

Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat

(2012) M. Futamura et al.   DIABETOLOGIA

Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp

(2012) Hans Ericsson et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Pancreatic Beta Cells in Very Old Mice Retain Capacity for Compensatory Proliferation

(2012) Miri Stolovich-Rain et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glucokinase Activators AZD6370 and AZD1656 Do Not Affect the Central Counterregulatory Response to Hypoglycemia in Healthy Males

(2012) Ensio Norjavaara et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Compensatory Recovery of Blood Glucose Levels in KKAy Mice Fed a High-Fat Diet: Insulin-Sparing Effects of PACAP Overexpression in β Cells

(2012) Yusuke Sakurai et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656

(2012) Michael J. Waring et al.   MedChemComm

Modulation of glucokinase by glucose, small-molecule activator and glucokinase regulatory protein: steady-state kinetic and cell-based analysis

(2011) Francis J. Bourbonais et al.   BIOCHEMICAL JOURNAL

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

(2011) G. E. Meininger et al.   DIABETES CARE

Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice

(2011) Maria Sörhede Winzell et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs

(2011) J.-i. Eiki et al.   MOLECULAR PHARMACOLOGY

Overcoming retinoic acid receptor-α based testicular toxicity in the optimisation of glucokinase activators

(2011) Michael J. Waring et al.   MedChemComm

Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092

(2011) Michael J. Waring et al.   MedChemComm

Effect of long-term treatment with a small-molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function

(2011) Akinobu Nakamura et al.   Journal of Diabetes Investigation

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat

(2010) Sumika Ohyama et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study

(2010) Riccardo C. Bonadonna et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia

(2009) Kara K. Osbak et al.   HUMAN MUTATION

Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 Diabetes

(2009) Gregory R. Bebernitz et al.   JOURNAL OF MEDICINAL CHEMISTRY

Assessing the potential of glucokinase activators in diabetes therapy

(2009) Franz M. Matschinsky   NATURE REVIEWS DRUG DISCOVERY

Glucokinase and molecular aspects of liver glycogen metabolism

(2008) Loranne Agius   BIOCHEMICAL JOURNAL

Impact of Small-Molecule Glucokinase Activator on Glucose Metabolism and β-Cell Mass

(2008) Akinobu Nakamura et al.   ENDOCRINOLOGY

Glucokinase activators in diabetes management

(2008) Matthew Coghlan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effect of high-fat diet on glucose homeostasis and gene expression in glucokinase knockout mice

(2007) T. Gorman et al.   DIABETES OBESITY & METABOLISM